Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. - Wikidata - wikimedia - TriplyDB

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

http://www.wikidata.org/entity/Q37693951

about

Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal.Pharmacogenetics guided anticoagulation.TRITON and beyond: new insights into the profile of prasugrel.Gender and anti-thrombotic therapy: from biology to clinical implications.Routine genotyping of patients on clopidogrel: Why the resistance?Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?

P2860

Q34131354-95404F52-AA57-4092-8B98-B07F118421E9 Q37599633-751B6FE6-9BDC-4480-867A-D2465ECFDED8 Q37808224-2737C794-FB3E-49A2-BA52-82F70B3CDA7C Q37925009-2F0F5599-399C-4BF5-9AA2-7519CFAAC188 Q38182428-5E2648DA-AA4C-4ECB-AA5F-9661A5238B48 Q42414159-6912B763-71B5-489A-9293-29D38A33FEAA Q42731695-5A61D023-15BF-4700-B06F-023DD73C2141

P2860

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

http://www.wikidata.org/entity/Q37693951

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

@en

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

@nl

type

label

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

@en

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

@nl

prefLabel

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

@en

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

@nl

P1433

Q37693951-BECB5971-7591-4058-B3EA-D8BEE43560C4

P1476

Q37693951-80E21E1F-0D9E-40B7-A7DB-D4FDA4CE8CBF

P2093

Q37693951-0B79590E-291B-40DC-A001-641367C72EA8

P2860

Q37693951-007BCC22-4EB2-43F0-81BD-ADEBBDA07F40

Q37693951-07AF5EFE-7D33-4781-95E2-B34CC9B0B5A5

Q37693951-13108B01-29B9-41C0-A93D-5CD904D7D095

Q37693951-13B60E1A-A396-45DB-8C6B-AF6C9602D459

Q37693951-17277254-D700-414D-9EE1-A35E7C15E897

Q37693951-17927BBA-4A9A-4C6B-9806-2A978130746B

Q37693951-1C3DD195-7475-479E-8A01-07C3BE665C6E

Q37693951-1D040F3C-D5BC-463A-821C-2BBCCD626523

Q37693951-25C05887-1784-4059-8D25-812C4E54EC77

Q37693951-27F6B182-8684-40F2-8473-22D091254774

P304

Q37693951-DAF6C7D4-56A4-4170-967F-9BF17D139264

P31

Q37693951-981ADABC-53A8-4683-90A7-C244613A19B5

P356

Q37693951-E0DAB075-3752-4855-80F4-5748C20A11C0

P407

Q37693951-797E581A-6D0A-4428-9038-633AC43B36F3

P433

Q37693951-17AAE90B-BDCA-4738-9F3C-D683E62E3DB0

P478

Q37693951-9EEDCAAE-7941-4D47-ADC2-F53399CDBCE4

P50

Q37693951-89DA0E5E-4815-41A4-BA40-6A34B432E2A1

Q37693951-DB1E6603-CBAD-4380-A45C-8E99E960C626

Q37693951-F9B0603F-75FB-4482-8227-5C65F40621DF

P577

Q37693951-CE108390-B083-4E60-BBB6-704543DBA2FE

P698

Q37693951-6B0A98A4-C07C-4E9C-B3CD-DA4EA5B69DB1

P921

Q37693951-7BEDE710-5B0C-4D23-86F3-D307C06AC091

P356

17425251003598878

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis

@en

P2093

Rosanna Abbate

http://www.w3.org/2001/XMLSchema#string

P2860

The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study

Aspirin resistance

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

P304

393-407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425251003598878

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Rossella Marcucci

Anna Maria Gori

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20163283

http://www.w3.org/2001/XMLSchema#string

P921